Alzheimer's and Parkinson's disease are late onset neurodegenerative diseases that will require 16 therapy over decades to mitigate the effects of disease-driving proteins such tau and α-synuclein 17 (α-Syn). We recently found that TRIM28 regulates the levels and toxicity of α-Syn and tau 18 (Rousseaux et al., 2016), however, how TRIM28 regulates α-Syn and whether its chronic 19 inhibition later in life is safe remained unknown. Here, we show that TRIM28 mediates the 20 SUMOylation of α-Syn and tau, and that genetic suppression of Trim28 in adult mice is 21 compatible with life. We were surprised to see that mice lacking Trim28 in adulthood do not 22 exhibit behavioral or pathological phenotypes, and importantly, adult reduction of TRIM28 23 results in a decrease of α-Syn and tau levels. These results suggest that deleterious effects from 24 TRIM28 depletion are limited to development and that its inhibition adulthood provides a 25 potential path for modulating α-Syn and tau levels. 26 27
Introduction 28
Neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) 29 occur in the later decades of life and have no curative therapy. Therefore, future treatments for 30 these disorders must be administered over decades, which means that safety profiles of 31 therapeutic targets are of utmost importance. The advent of alternative therapies such as 32 antisense oligonucleotides, gene therapy and immunotherapy, together with traditional 33 2009). Given the importance of TRIM28 for development, it remains unclear whether TRIM28 is 48 critical for adult brain function, and whether it may safely be targeted in adulthood. Specifically, 49 two questions remain related to the targeting of TRIM28 pharmacologically: 1) Is there a 50 pharmacologically tractable domain in TRIM28 that could be targeted by a drug? 2) Is genetic 51 4 suppression of TRIM28 in the brain and throughout the body tolerated in adulthood? To test this, 52 we performed studies to pinpoint the mechanism by which TRIM28 regulates a-Syn and tau and 53 generated two animal models to disrupt Trim28 in vivo, thus establishing its druggability in 54 adulthood.
56
Results and Discussion 57 We previously found that TRIM28 regulates the post-translational stability of a-Syn and tau and 58 that this effect is mediated by two critical cysteines in its RING domain (C65 and C68; 59 (Rousseaux et al., 2016) ). We therefore hypothesized that TRIM28 exerted E3 SUMO ligase 60 activity on of a-Syn and tau (Liang et al., 2011; Neo et al., 2015; Yang et al., 2013) . To first test 61 whether SUMOylation itself regulates the levels of a-Syn and tau, we inhibited the sole E2 62 SUMO ligase, UBC9, via RNAi and pharmacological inhibition (using Viomellein (Hirohama et 63 al., 2013)). We found that both approaches were sufficient to decrease a-Syn and tau, suggesting 64 that SUMOylation indeed regulates their steady state levels (Figure 1A) . We next asked whether 65 TRIM28 mediates the SUMOylation of a-Syn and tau. We first tested this in cells and found that 66 knockdown of endogenous TRIM28 decreased native a-Syn and tau SUMOylation whereas 67 ectopic overexpression of TRIM28 increased their SUMOylation (Figure 1B) . Interestingly, 68 when we mutated a catalytic RING domain of TRIM28 (C65A/C68A), we could inhibit a-Syn 69 and tau SUMOylation (Figure 1B) . This was consistent with our previous findings that mutating performed SUMOylation assays on endogenous a-Syn and tau from brain lysates (under 73 5 denaturing conditions) from wild-type and Trim28 +/mice. We found that a-Syn and tau 74 SUMOylation were significantly reduced in Trim28 haploinsufficient mice ( Figure 1C) .
75
TRIM28 has several important functions throughout the cell, and its loss of function in 76 mice is embryonic lethal. We therefore asked whether one of its domains can be specifically 77 targeted for future therapeutic use without disrupting the others. Given that two conserved 78 critical cysteine residues in its RING domain (Figure 1-figure supplement 1A) regulate the 79 bulk of TRIM28 function toward a-Syn and tau, we hypothesized that mutating its endogenous 80 catalytic activity would be the most promising approach. We therefore generated a knockin 81 mouse carrying mutations in its RING domain (Figure 1-figure supplement 1B) . We found that 82 mutating these residues, despite decreasing a-Syn and tau levels significantly, caused a dramatic 83 destabilization of TRIM28 protein (Figure 1-figure supplement 1C-D) . Moreover, 84 homozygosing these E3 mutant mice caused embryonic lethality, a feature consistent with the 85 generation of a null allele. Thus, mutating the RING domain of TRIM28 decreases a-Syn and 86 tau levels, but does so by disrupting its structure and stability (Figure 1-figure supplement 1D) . 87 Since TRIM28 has critical roles in development, we next asked whether we could bypass 88 these defects by knocking down Trim28 in the postnatal mouse brain (Figure 2-figure   89 supplement 1A). We used an AAV carrying both an shRNA targeting Trim28 and a YFP 90 reporter. We found that the virus was widely expressed throughout the brain (Kim et al., 2013) 91 and that mice receiving and shRNA against Trim28 had a 75% depletion of Trim28 in their brain 92 (Figure 2-figure supplement 1B) . Importantly, these mice developed normally until at least 10 93 weeks of age. We evaluated cortical and hippocampal thickness and astrocytosis in these mice 94 and did not note any significant defects (Figure 2-figure supplement 1C (Cammas et al., 2000) . We waited until the 100 animals were 8-12 weeks old before starting a 4-week tamoxifen regimen to ablate Trim28 101 (Figure 2A) . To our surprise, we found that adult depletion did not result in early lethality nor 102 overt phenotypes. Instead, adult knockout mice lived for the duration of the study (30 weeks post 103 tamoxifen injection, Figure 2B ). We tested whether Trim28 is effectively ablated in these mice 104 and found that Trim28 levels were reduced by over 75% in each tissue tested (both at the RNA and tau levels were also decreased in multiple brain regions, corroborating our previous findings 107 using germline haploinsufficient mice (Rousseaux et al., 2016) .
108
An important aspect of measurable safety margins in the depletion of a gene is its impact 109 on neuronal function. To assess whether loss of Trim28 in adult mice impacts brain structure and 110 function, we performed a battery of behavioral and histological tests. We found that Trim28 111 adult knockout mice behaved similarly to their control littermate counterparts in every test 112 assayed. Specifically, no defects were observed in motor behavior, anxiety, perseverative 113 movements and memory (Figure 3A-H) . Consistent with this, we could not discern any gross 114 histological defects nor signs of inflammation (as measured by GFAP immunoreactivity) in the 115 brain (Figure 4A-C) . We further tested Trim28 levels via immunostaining and found that, while 116 Trim28 was highly expressed in the brain (confirming our western and qPCR results), it was over 117 75% depleted in the adult knockout (Figure 4-figure supplement 1A) . A previous study 118 7 highlighted several gene expression changes in mice lacking Trim28 in forebrain excitatory 119 neurons starting from postnatal day 14 (Jakobsson et al., 2008) . We tested the expression of these 120 genes in the hippocampus via qPCR and found that, while the directionality of changes was 121 consistent with the previous study, there was a broad dampening of this effect in the adult 122 knockout mice (Figure 4-figure supplement 1B) . This may be due to the later stage depletion of Trim28 knockouts.
127
Given that the adult knockout affects the whole body, we examined regions of the body 128 that could be vulnerable to Trim28 loss-of-function induced toxicity. We assessed general 129 morphology of the heart, liver and spleen and found no discernable defects in the adult knockout 130 mice compared to littermate controls (Figure 4-figure supplement 2) . Moreover, blood 131 chemistry in these mice appeared normal (Figure 4-figure supplement 3) . 132 Taken together, our study suggests that adult depletion of more than 75% of total Trim28 133 from the mouse body is safe. This is consistent with reports that deletion of TRIM28 in 134 terminally differentiated muscle is safe (Dalgaard et al., 2016) . These findings hold important 135 implications for therapeutic targeting of Trim28 in diseases such as AD and PD where an 136 inhibitor targeting TRIM28 may hold promise in the future. An important point of consideration 137 moving forward into therapeutics is the mechanism by which TRIM28 regulates the steady state 138 levels of a-Syn and tau. While our data suggest that TRIM28 forms a complex with a-Syn and 139 tau (Rousseaux et al., 2016) and mediates their SUMOylation, we were not able to reconstitute 140 this complex in a cell-free system, suggesting that other factors may be at play. Furthermore, Tamoxifen injections were performed as previously described (Sztainberg et al., 2015) . Briefly, 209 starting at 8-12 weeks of age, tamoxifen or vehicle (peanut oil) was injected intraperitoneally at a 210 dose of 100 mg/kg, three times a week for four weeks. Mice were left to recover for at least two 211 weeks before proceeding with behavioral, biochemical and histological assessment. Transfection efficiency was measured by looking at YFP fluorescence (average ~60-75% cells 220 infected) and knockdown efficiency was determined by qPCR. AAV production and titering was 221 performed as previously described (Kim et al., 2008) . 12 AAV delivery was carried out in neonatal (P0) FVB mouse pups as previously described 223 (Kim et al., 2013) . Briefly, neonatal pups (<8 hours from birth) were separated from lactating 224 dams and anesthetized on ice. 1x10 11 viral genomes were injected per ventricle (total of 2x10 11 225 genomes per mouse) and mice were left to recover on a heated pad before returning them to their 226 mother. All procedures were performed in a BSL2-contained area and mouse bedding and Mice were anaesthetized with isoflurane and blood was collected from the retro-orbital sinus.
274
The animal under general anesthesia is gently scruffed and a capillary is inserted into the medial 275 canthus of the eye. Applying a slight pressure to the capillary allows the blood flow to be 276 directed to a collection tube. After letting the blood coagulate for 30 min, the serum is collected 
